Long Cast Advisers, a distinguished registered investment advisory firm, recently unveiled its Q2 2026 investor letter, shedding light on its impressive performance and strategic outlook. The firm recorded a robust 20% increase in earnings during the second quarter, elevating its year-to-date returns to a commendable +19%. While these figures surpassed some market benchmarks, they still maintained a lead over certain international small-cap funds. Since its establishment in 2015, Long Cast Advisers has achieved a cumulative return of 343%, representing a 15% compound annual growth rate, a testament to its philosophy of concentrated, long-term investments in small and micro-cap enterprises. Despite its success, the firm maintains a cautious stance on the current economic landscape, advocating for patience and resilience while consciously avoiding excessive leverage and market volatility.

Within its Q2 2026 investor correspondence, Long Cast Advisers specifically drew attention to NRC Health (NASDAQ:NRC). This entity specializes in delivering analytical tools and insights to enhance the patient and employee experience within healthcare systems across the United States. Formerly recognized as National Research Corporation, the company officially rebranded to NRC Health in April 2026. As of August 7, 2026, NRC Health's stock closed at $20.34 per share, translating to a market valuation of $449.9 million, and demonstrating a year-to-date appreciation of 9.30%. Although the company experienced a marginal decline of -6.02% over the preceding month, its shares have surged by an impressive 35.95% over the past 52 weeks.

Long Cast Advisers expressed considerable optimism regarding NRC Health, citing the company's strategic evolution from a founder-led operation to a professionally managed enterprise. This transition is expected to unlock significant advantages, including the deployment of a growth-oriented, incentivized, and entrepreneurial executive team to steer this well-established and recognized brand. The firm noted that NRC Health operates in a sector characterized by strong free cash flow generation, and its market position has been further solidified by the recent merger of two primary competitors in a substantial private equity-backed transaction valued at $6.5 billion. This confluence of factors paints a promising picture for the company's future trajectory.

Further supporting this positive outlook is tangible quantitative data, including the recent announcement of NRC Health's largest contract in its history, which has resulted in the highest 12-month backlog ever recorded. The firm also observed a consistent increase in deferred revenues, typically a precursor to future sales growth. Moreover, management's indication that the second year of the aforementioned record contract is projected to be substantially larger than the first suggests that the 12-month backlog could expand even further in the coming year, indicating ample capacity for continued expansion. Long Cast Advisers continues to strategically augment its holdings in NRC Health as opportunities arise.

It's worth noting that NRC Health (NASDAQ:NRC) is not featured among the "40 Most Popular Stocks Among Hedge Funds Heading Into 2026" in our internal database, which registered 8 hedge fund portfolios holding the stock at the conclusion of the first quarter, consistent with the previous quarter. While acknowledging NRC Health's investment potential, we believe that certain artificial intelligence (AI) stocks present more substantial upside potential with comparatively lower downside risk. For investors seeking an exceptionally undervalued AI stock poised to benefit significantly from impending trade policies and the domestic manufacturing trend, we recommend exploring our comprehensive report on the optimal short-term AI investment opportunities.

This analysis underscores NRC Health's compelling trajectory, fueled by robust contracts, a strategic shift in leadership, and a favorable market environment. The company's record backlog and growing deferred revenues signal continued financial strength and expansion potential, positioning it as an attractive prospect for growth-focused investors.